ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Stemness reducible effects of glyasperin A against NCCIT teratocarcinomas.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
There is a great deal of interest in cancer stem cells (CSCs) in cancer therapy related to hallmarks of stemness and capacity for tumor relapse. Inhibition of CSCs by natural compounds represents a potential therapeutic approach. Thus, this study aimed to investigate potential effects of glyasperin A (GlyA) against CSCs by regulating possible stemness markers and signaling pathways as well. The NCCIT cell, a cell line derived from extragonadal germ cell tumors, was used as the cancer stem cell model for this study. The growth of teratocarcinoma cells under GlyA treatment in two-dimensional (2D) and three-dimensional (3D) cell culture patterns was revealed by MTT assay. The flow cytometry analysis was accessed to determine the expression of stemness surface markers and cell cycle arrest. In addition, the immunoblotting and human phospho-kinase array were applied to determine the possible target molecules in NCCIT cells under GlyA intervention. The collected results revealed that GlyA strongly inhibited the growth of NCCIT cells. The compound made cell cycle progression from the G0/G1 to the S phase. GlyA induced apoptosis by upregulating Bax and phosphorylated ERK1/2 protein levels. On the other hand, it also downregulated the expression of several transcription factors (Nanog, Oct4, c-Myc), which are closely correlated with stemness. Moreover, the levels of some proteins involved in the Akt/mTOR/IKK signaling pathways, which play critical roles in maintaining the self-renewal and proliferative features of CSCs, were also decreased. These results show that GlyA affects multiple targets that sustain the stemness features and proliferation or cell death of CSCs.
Indexed as
Identifiers
40478339What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.